IMMU-20. ADVANCED AGING INCREASES IMMUNOSUPPRESSIVE IDO1 LEVELS THAT ARE UNINHIBITED BY IDO1 ENZYME INHIBITOR TREATMENT IN MODELS OF GLIOBLASTOMA

Immunotherapy has failed to improve the overall survival (OS) of adults with GBM in all phase III clinical trials to-date. Somewhat less appreciated is that, de novo GBM is a disease associated with a median age of diagnosis at 64 years old. Because of the strong association between advanced aging a...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Ladomersky, Erik, Zhai, Lijie, Lauing, Kristen, Qian, Jun, Otto-Meyer, Sebastian, Savoor, Rohan, Wainwright, Derek
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2019
נושאים:
Immunology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847513/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.513
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים